The increasing demand for recombinant therapeutic proteins has placed significant pressure on the biopharmaceutical industry to develop high-yielding, mammalian cell-based production systems. Current efforts to increase the production of recombinant proteins by mammalian host cells largely proceed by the lengthy screening of clonal derivatives rather than by directed genetic or metabolic engineering. However, the advent of systems biology has created a new set of tools that will ensure that future engineering strategies will be informed by an understanding of the genetic/regulatory and metabolic networks that determine the functional competence of mammalian cell factories in vitro. In this review we summarize recent systems-level studies that utilize genome-scale analytical tools to analyse the functional basis for key production process characteristics such as high cell-specific productivity, correct product processing and rapid cell proliferation in the in vitro environment. We also describe the use of highthroughput -omic technologies to investigate how mammalian cell factories respond to environmental and metabolic perturbation.
INTRODUCTION
The production of recombinant proteins by the biopharmaceutical industry will serve a global market with a projected size of USD$70 billion by 2010 [1, 2] . The majority ($70%) of recombinant therapeutic proteins are produced by mammalian cells in culture and this proportion is increasing. The sustained rapid growth of this sector is driven by the relatively high success rate of recombinant protein drugs in trials. For example, $18-29% of recombinant monoclonal antibodies (MAb's) in development succeed to market [3] , and the forecast annual growth rate of the recombinant MAb sector is 21% [4] . It is anticipated that by 2015 biopharmaceuticals will constitute at least 30% of the total pharmaceutical market.
Chinese hamster ovary (CHO) cells are by far the most widely utilized mammalian cell type engineered to produce correctly folded, fully glycosylated recombinant proteins [2] , although other host cells are also employed (e.g. murine myeloma NS0 and Sp2/0). Over the last 15 years extensive empirical optimization of mammalian cell-based production systems has substantially increased both volumetric concentration of recombinant product and shortened cell line development time [5] . In the case of recombinant MAb's, volumetric productivities exceeding 5 g/l are now achievable in a drastically reduced development time [6] . As discussed below, this is largely a consequence of the systematic optimization of viable cell lifetime (e.g. [7] ) and the advent of rapid screening technologies able to identify and isolate productive transfectants [8] .
Recent successes in improving the productivity of mammalian cell production systems have been achieved despite a dearth of specific knowledge of how engineered cells successfully function in vitro.
The absence of such knowledge means that crucial cell line characteristics such as high specific productivity, correct product processing and rapid cell proliferation within the synthetic environment are currently obtained by the lengthy screening of clonal derivatives rather than by directed genetic or metabolic engineering. Using this strategy, innate or introduced (i.e. from recombinant DNA) genetic heterogeneity is harnessed effectively but blindly. Without an understanding of the integrated control of cell function in culture, or the means of systematically obtaining it, improvement and re-design of animal cell phenotypes for diverse purposes will proceed by trial and error, utilizing single gene engineering strategies derived, albeit rationally, from studies utilizing other eukaryotic systems. As discussed by Bailey et al. [9] , this classical 'targeted' approach to cell engineering has yielded mixed and often disappointing results.
The advent of systems biology (the combination of high information content bioanalytical technologies, bioinformatic data organization and mathematical modelling) has created a new paradigm for understanding the control of complex cellular phenotypes [10] . This new set of tools will enable us to move beyond blind screening technologies towards cell engineering strategies that are based on knowledge of the genetic/regulatory networks that determine the functional competence of mammalian cell factories in vitro. We can anticipate that a new 'systems biotechnology' that can effectively generate predictions of cell performance within the engineered environment, or the effect of genetic manipulations, will greatly facilitate the development of new bioprocesses and bioproducts. The most effective approaches will integrate data streams derived from more than one level of networked cellular organization [11] , and move beyond comparative surveys of cellular components towards more coordinated approaches [12, 13] . For example, it will be necessary to correlate genetic inputs (cell component availability, turnover and biomolecular interactions), with information on key output rates, such as precursor flux, biomass accumulation, cell proliferation, recombinant gene expression and secretion. For mammalian cells this is a substantial task that requires a multidisciplinary approach [14] . Progress in this area will be greatly facilitated by the increasing availability of genome-scale models of mammalian cell metabolism [15, 16] .
In this review, we describe recent systems-level studies that focus on the functional characteristics of host mammalian cells relevant to their use as vehicles for biopharmaceutical protein production. Underpinning most work is the desire to understand how we rationally direct genetic engineering for improved performance, identify biomarkers that can be used to pre-select cells with desirable characteristics or design new tools to predict cell function.
CELL PRODUCTIVITY
Volumetric product yield is a function of two basic culture parameters, (i) cell-specific production rate (qP) and (ii) the integral of viable cell concentration (commonly calculated as cell time per unit volume) during culture. For typical fed-batch production processes the ideal combination is a rapid accumulation of productive cellular biomass maintained at high viable cell concentration for as long as possible. In recent years increased productivity has largely been a consequence of the systematic optimization of media formulation and rational design of feeding regimes which primarily facilitate increased accumulation of cellular biomass in vitro and to a much lesser extent cell-specific production rate [5] . In fact, the basic host cell (e.g. CHOK1 derivatives) and gene expression systems used by industry (e.g. glutamine synthetase, dihydrofolate reductase selection/amplification systems) have not developed significantly for over 10 years with, for example, the specific productivity of recombinant MAb producing cells in batch culture still typically 20-50 pg/cell/day [17, 18] . Developments in mammalian gene expression technology to increase recombinant gene copy number or transcriptional activity have occurred subsequently, e.g. use of more active promoters [19] , targeting of rDNA to transcriptionally active sites [20] , genomic DNA sequences [21] , chromatin opening elements [22] , matrix attachment regions [23] , etc. However, in practical terms, whilst these technologies may increase the proportion of stable transfectants with higher qP [24] , step changes in cell-specific production rate have not been achieved.
Kinetic models of cellular production processes
The cell-specific recombinant protein production rate (qP) is a function of the relative rates of a diverse variety of cellular processes; recombinant gene transcription, mRNA decay, mRNA translation, co-translational glycosylation, nascent polypeptide folding, ER-associated degradation and inter-vesicular transport of fully assembled protein.
Crucially, we still do not systematically understand how the host cell coordinates and regulates the dynamic cellular processes that contribute to recombinant protein synthesis during production processes. In this regard, recombinant MAb's have been most intensively studied. The sequence of MAb assembly reactions in vivo is known [25] and it is likely that particular synthetic reaction steps are more limiting than others. The first kinetic models of MAb synthesis in hybridomas by Bibila and Flickinger [26, 27] suggested that the rate-limiting step of Mab synthesis shifts from Mab assembly in fast-growing cells to mRNA translation in slow-growing cells. More recently, Gonzalez et al. [28] have produced a simplified, theoretical metabolic control analysis of MAb synthesis. This model predicts shared control of flux to secreted antibody between cellular synthetic reactions, assembly processes and translocation events, where control varies with imposed constraints (precursor availability, recombinant gene expression levels, etc). More recently, Ho et al. [29] have modelled MAb production by GS-NS0 cells. Using a global sensitivity analysis they report that specific transcription and translation rates for recombinant heavy and light chain genes/mRNA's remain important throughout a production process, although recombinant mRNA translation and half-life assume an increasing priority as culture progresses into stationary phase. These conclusions correlate with a recent study from this laboratory. Using a combination of biomolecular and proteome analyses Stansfield etal. [30] demonstrated that although large changes in qMAb occur during a fed-batch culture of GS-NS0 cells, the cellular proteome remains remarkably constant, varying primarily with cell growth rate. However, during culture the cellular constraints on MAb production vary. Initially qMAb correlates with increasing heavy chain mRNA abundance, however from mid-exponential culture onwards this relationship does not hold, whilst heavy and light chain mRNA abundance and rate of polypeptide synthesis remain relatively high, qMAb declines indicating a progressive restriction in cellular MAb production downstream of protein synthesis.
Other factors affecting the kinetics of MAb synthesis have also proved amenable to modelling. For example, based on a proteomic analysis of GS-NS0 cell lines producing a recombinant IgG 4 MAb in James's laboratory [31] , it was hypothesized that excess LC polypeptide was necessary but not sufficient for efficient MAb folding and assembly in mammalian cells. Subsequently, this group experimentally demonstrated more efficient use of MAb HC gene at excess LC production, and derived a mathematical model of MAb folding and assembly for prediction of optimal HC:LC gene ratio [32] . These conclusions have been confirmed in Sharfstein's laboratory [33] . However, no models account for important parameters such as internal co-regulation of cellular processes at elevated recombinant gene expression levels. For example, it is important to note that mRNA translation rate, ER-associated degradation and ER folding capacity are linked via intracellular signalling pathways such as the unfolded protein response, and that as for antibody-producing plasma cells in vivo, these are likely to be a functionally relevant interaction with respect to recombinant protein synthesis [34, 35] .
Many genetic engineering strategies to increase qP have proved intractable [34] . For example, inhibition of cell proliferation to apparently increase qP via expression of cell cycle regulators such as p21 results in the formation of larger cells, not more productive cell biomass per se [36] . However, as shown by previous work on immunoglobulin folding and assembly [37] and as predicted by a kinetic model of MAb production [38] , a good candidate for engineering is the redox reaction catalyzed by protein disulphide isomerase (PDI), which enables the formation of heavy chain-light chain and HC-HC disulphide bonds in the ER. This has been shown to facilitate expression of recombinant immunoglobulins by baculovirus-infected insect cells [39, 40] and Borth and co-workers [41] have shown that overexpression of PDI in CHO cells increases qMab by 40%. Interestingly, two independent proteomic investigations have revealed that PDI proteins and other ER chaperones known to interact with nascent MAb polypeptides such as endoplasmin are increased in abundance in NS0 cells with high MAb productivity [31, 42, 43] .
The effect of cell line genetic heterogeneity on specific productivity
Aside from kinetic models of recombinant product synthesis in single cells, perhaps a more fundamental consideration is whether particular cells within a population of parental cells are more suited to act as production vehicles than others, i.e. to what extent is clonal variation or genetic heterogeneity a determinant of functional competence? Clearly there can be heterogeneity in the functional state and organization of introduced recombinant genes [44, 45] , and cell-to-cell variation arising from point mutations, epigenetic alteration or chromosomal aberrations within the host cell genome [46] can result in clonespecific differences in a variety of gross functional characteristics such as cell growth [47] , protein glycosylation and response to culture environment [48, 49] . Accordingly, isolation of murine and rat cell lines has been shown to be a major determinant of genetic heterogeneity when the transcriptome of clonal derivatives was compared using oligonucleotide microarrays [50] . In this experiment, clonal variation in gene expression exceeded that induced by recombinant protein induction. Therefore, it is perhaps unsurprising that recent -omic studies comparing engineered mammalian cells with different specific productivity have identified significant clonal variation. However, the extent to which these differences have been correlated to cell line-specific productivity (qMAb) varies. Recent proteomic studies in our laboratory comparing GS-NS0 murine myeloma cell lines with different qMAb have shown significant co-variation between qMAb and cell line-specific variation in the NS0 proteome. In initial studies comparing the relative abundance of single proteins, molecular chaperones known to be associated with MAb folding and assembly (notably BiP, PDI and endoplasmin) were significantly increased in abundance in the cell line with high qMAb [31, 43] . A subsequent detailed statistical analysis of the proteomic data showed that six of nine functional groups of proteins were significantly increased in abundance in cell lines with elevated qMAb: ER chaperone, non-ER chaperone, cytoskeletal, cell signalling, metabolic and mitochondrial categories [51] . Importantly, there was no evidence of an unfolded protein response-derived induction of gene expression in high producing cell lines, indicating that the observed changes in the proteome were not themselves induced by the recombinant protein accumulation. These data imply that a number of cellular systems act in synergy to influence cell-specific production rate (qP): qP is not just a function of cloned gene copy number in an otherwise 'unemployed' host cell factory.
Other -omic studies on NS0 and CHO cells with varying qP have identified a range of differentially expressed genes and proteins with altered relative abundance. Using proteomic data based on 2D-PAGE and MS, Hayduk and Lee [52, 53] analysed the proteome of a series of selected CHO clones producing recombinant secreted alkaline phosphatase (SEAP) to varying levels according to degree of recombinant gene amplification by dhfr/ methotrexate. Over 20 proteins of diverse function were found to exhibit a conserved increase in abundance with qP, including cytoskeletal proteins. The authors showed that modulation of actin capping activity in CHO cells using the inhibitor cytochalasin D increased qP up to 3-fold. More recently, a study by Seth et al. [42] combined analyses of the transcriptome and proteome of 11 NS0 cell lines producing a recombinant MAb. Unfortunately no cell growth or specific productivity data were reported, although the 'high-producing' cell lines were 2-to 11-fold more productive than low producing cell lines. A high degree of consistency between transcriptome and proteome data was reported, and a biological network analysis indicated that protein synthetic and cell growth/death pathways were altered in cells with high MAb productivity. In contrast, another transcriptomic study comparing non-transfected NS0 and a single GS-NS0 cell line producing a recombinant MAb reported that protein synthetic and ribosomal genes were more highly expressed in the non-producing WT cells [54] .
What conclusions can be drawn from these data? Despite the fact that recombinant protein production is not an objective function for (for example) CHO cells, it is likely that discrete cells within populations are more suited to the imposed burden of recombinant protein production than others. Genetic heterogeneity within the parental populations means that not all host cells are the same. It can be argued that all -omic studies indicate that cells with increased productivity have an elevated 'capacity for flux' in one or more pathways. However, the way in which excess capacity manifests itself may vary according to different constraints. For example, the demands one recombinant protein places upon the cellular folding and assembly machinery will be different to the demands of another. As reported recently, induction of recombinant transferrin production in CHO cells stimulates stress protein synthesis and a reduction in cell growth [55] . Clearly in this case a cell line that harboured an elevated folding and assembly capacity would be more capable than other cells of combining an ability to produce the recombinant protein as well as it's own biomass without invoking a cytostatic stress response to an accumulation of unfolded recombinant protein such as the unfolded protein response [56] . Interestingly, examples of whole organelle cell engineering based on this concept have been published recently. Expression of the bioactive form of the UPR transactivator X-Box Binding Protein 1 (XBP-1s) in CHO cells both expanded the endoplasmic reticulum and increased recombinant protein production capacity [57] , although in another study it was concluded that XBP-1s expression was only effective when the existing secretory pathway was saturated by highlevel recombinant protein production [58] . More generally, if protein-specific, cell type-specific and production process variables are constrained (e.g. MAb production in a generic fed-batch process using chemically-defined media), then it is likely that there will be a generally predominant cellular solution or functional bias favouring hyper-productivity, as per natural antibody hyper-producers in vivo, plasma cells [59] . As discussed recently, hyper-productive cell lines are likely to have a range of superior attributes [60] .
CELL SURVIVAL IN A SYNTHETIC ENVIRONMENT
Fed-batch culture of mammalian cells for recombinant protein manufacture is predominantly based on the use of cell lines capable of proliferation as single cells in suspension in a chemically-defined synthetic environment. This is an environment lacking exogenous growth factors, cell-matrix and cell-cell contacts-all of which usually contribute to proliferation and survival of epithelial cell types such as CHO cells. Therefore, for manufacturing platforms based on CHO cells for example, a substantial shift towards single cell autonomy is a necessary prerequisite for successful bioprocess development. This is usually achieved by long-winded empirical 'adaptation' processes which successively select clonal derivative(s) able to proliferate as single cells in suspension in a protein and (often) mitogen free medium [61] . Very little is known of the underlying biological adaptations which permit particular cell clones to survive and proliferate in a desirable synthetic environment. A notable exception is recent work on cholesterol auxotrophy of murine myeloma (NS0) cells. An initial study utilizing transcriptional profiling and 2D-PAGE-based proteomics to compare wild-type cholesterol-dependent NS0 cells with a cholesterol-independent revertant revealed many differentially regulated genes associated with lipid biosynthesis, metabolism and central energy transduction [62] . Subsequently, it was discovered that the wild-type cholesterol auxotrophy was, in fact, a consequence of a single gene metabolic deficiency in the conversion of lanosterol to lathosterol [63] . Over expression of the enzyme responsible, 17-hydroxysteroid dehydrogenase type 7 in wild-type cells enabled cholesterol-independent growth.
Cell death by apoptosis may be a factor in determining volumetric product yield obtained from fed-batch production systems, and much effort has been made to genetically engineer host cells to extend culture lifetime [64] . Recent transcriptomic studies by Wong et al. [65, 66] have described the origins of apoptosis in batch and fed-batch cultures of CHO cells and identified pro-and anti-apoptotic genes that served as effective targets for genetic engineering strategies to delay cell apoptosis in vitro. Nevertheless, how production cell lines such as CHO achieve cell growth and proliferation without added mitogens or surface attachment in chemicallydefined suspension culture cannot yet be explained. For many epithelial cell types cultured in vitro, including CHO cells, disruption of integrinmediated attachment to the extracellular matrix initiates apoptosis; termed anoikis in this context [67] . For CHO cells, lack of integrin-mediated attachment has been shown to disrupt a signalling cascade, which normally results in expression of the anti-apoptotic protein Bcl-2 [68] , and inhibition of this survival pathway by serum withdrawal can be avoided by expression of a variety of activated signalling pathway intermediates [69] . Integrins are also known to potentiate growth factor receptor (tyrosine kinase) signalling cascades [70] , interact extensively with the cytoskeleton, mediate cell-cell cohesion and coordinate mechanotransduction, all of which are highly relevant to cell performance in vitro. Similar considerations apply to cell surface proteins involved in cell-cell contact. Clumped CHO cells are known to form cell-cell junctions involving cytoskeletal components and it is likely that other gap junction/adherens proteins (e.g. cadherins, catenins) may also be involved in signalling pathways that regulate cell survival.
Parental CHO cell cultures typically require a supply of exogenous growth factor proteins which interact with receptor tyrosine kinases on the cell surface to stimulate cell growth and proliferation via signalling cascades. It is not generally known how production cell lines adapted to suspension culture assume independence of mitogenic factors and adhesion. We can only speculate that, as for cancer cells, the loss of cell cycle control may involve mutation of signalling factors that contribute to the control of cell cycle checkpoints. For example, deregulated overexpression of cyclins D and E involved in G 0/1 to S phase transition is typical of many cancers [71] . In this respect, expression of cyclin E in CHO cells has previously been shown to substitute for addition of basal fibroblast growth factor to culture by promoting cell growth with a rounded morphology in protein-free medium [72] . Alternatively, other media components may substitute (e.g. zinc [73] ) or, as in the case of cancer cell lines that acquire autocrine growth capability, adapted cells may acquire the ability to produce autocrine growth factors, as recently suggested for NS0 cells [74] .
In general there is very limited knowledge of the fundamental ways in which production cell lines acquire a capability for autonomous growth and regulate their environment and interactions. Alterations to intracellular signalling pathways that control CHO cell proliferation in the production environment are not well understood and this lack of knowledge limits our capability to positively engineer cells for increased growth and proliferation as opposed to a negative regulation (inhibition) of cell proliferation as a biphasic culture strategy [36, 75] . Characterization of signalling pathways themselves at the systems level may be an option. For example, variation in signalling pathway activation at the single cell level has been analysed by multi-parameter flow cytometry using fluorophore-labelled anti-phospho antibodies [76, 77] . This may be a method to rapidly screen parental populations for signalling pathway profiles that correspond to an autonomous phenotype and to model signalling interactions using, for example, Bayesian networks [78] .
CELLULAR RESPONSE TO ENVIRONMENTAL AND METABOLIC PERTURBATION
A substantial proportion of recent -omic studies have compared host cell response to a change in their environment, either chemical (e.g. sodium butyrate, dimethyl sulphoxide) or physical (e.g. mild hypothermia, osmolality). Such environmental perturbations are either deliberately applied to increase cell productivity in vitro (butyrate, DMSO, mild hypothermia) or occur as an indirect consequence of other manipulations such as controlled culture feeding which increases medium osmolality. All these environmental changes reduce cell proliferation, and cellular response is likely to be cell line specific [48, 49] .
Sodium butyrate acts as a histone deacetylase inhibitor, promoting chromatin opening, transcriptional activation of recombinant genes, as well as apoptosis [79, 80] . It has been used extensively to increase the cell-specific productivity of a range of host cell types [81, 82] . Cytogenetic analyses of CHO cells has shown that low concentrations of butyrate can induce aneuploidy and cytoskeletal abnormalities [83] , and induction of recombinant protein expression by butyrate may itself induce the expression of endoplasmic molecular chaperones such as BiP (GRP78) [84, 85] . Given the above, it might be expected that recent genome-scale analyses of butyrate treated cells would demonstrate significant and broad changes in gene expression. However, this has not proved to be the case. In an initial transcriptomic study, De Leon Gatti et al. [86] showed that under 5% of 2602 CHO cell transcripts probed using a CHO microarray were differentially expressed on treatment of cells with 1 mM butyrate for 27 h. Unexpectedly, most transcripts were downregulated, indicative of a global down regulation of protein synthesis and mRNA translation. In contrast, the recombinant product and ER chaperones such as BiP were significantly up-regulated. A further study by the same group utilizing a larger CHO cDNA microarray in combination with proteome analysis by 2D gel electrophoresis [87] has confirmed the limited effect of butyrate on the scale and extent of differential gene expression and proteome alteration in CHO cells (under the conditions employed). The transcriptomic data revealed a greater effect of butyrate on protein processing and vesicular transport genes, implying that this may contribute to increased productivity of butyrate treated cells. Whether these changes are an indirect consequence of stress-pathway (e.g. UPR) induction by the recombinant gene product itself is open to question.
The alkyl sulphoxide DMSO is widely used as a cryoprotectant during the mammalian cell freeze/ thaw process. Previously known for its ability to promote more efficient transfection of mammalian cells with recombinant DNA [88, 89] and infection with viruses [90] , DMSO has also been found to increase CHO cell-specific productivity at concentrations of 0.3-1% (v/v) [91] [92] [93] . Despite these effects, it's mode of action remain unclear. In an attempt to clarify this, Li et al. [94] analysed the effect of DMSO on CHO cells expressing recombinant hepatitis B surface antigen using proteome analysis based on 2D gel electrophoresis. Of 52 protein spots identified by MALDI-MS, seven proteins exhibited a (statistically unproven) reduction in abundance on treatment of cells with 1.5% (v/v) DMSO; four glycolytic enzymes, two molecular chaperones and cytochrome b5. No specific conclusions can be drawn from this analysis and the molecular effects of DMSO on cells remain unclear.
A mildly reduced culture temperature (e.g. 31-33 C) can be utilized to increase volumetric productivity. At this sub-physiological temperature CHO cells usually arrest in G 0/1 phase of the cell cycle yielding an extension in viable cell lifetime and, dependent upon the protein and the pre-existing specific productivity of a cell line, increased cellspecific productivity [48, [95] [96] [97] [98] [99] . Reduced culture temperature may also be used to increase transient production of recombinant proteins [100] , despite generally reduced protein synthetic rates. Increased cell-specific productivity caused by mild hypothermia is mediated in part by the increased stability of recombinant and cellular mRNA's leading to an increase in their cellular abundance, coupled with the ability of cells to maintain active anabolic processes without cell proliferation [101, 102] . The induction of eukaryotic cold-shock proteins (CSP's) with RNA chaperone activity such as RBM-3 and CIRP is thought to underpin the ability of mammalian cells to function at reduced temperatures. The molecular function of CSP's and mechanism of mammalian cell response to sub-physiological temperatures has recently been reviewed [103] . However, published -omic studies do not substantially add to an overall understanding of cellular function or productivity at reduced temperature. Of the limited number of studies, an analysis of the transcriptome of mouse NIH 3T3 cells at 32 C reported that 10% of genes exhibited an altered expression, with similar numbers of genes up-and down-regulated [104] . Genes involved in several pathways were altered; transcription, signal transduction, apoptosis. Interestingly, genes associated with cholesterol biosynthesis were up-regulated, correlating with an increase in plasma membrane cholesterol content. Two other microarray analyses comparing NS0 cells at 22, 34 and 37 C [105] and CHO cells at 33 and 37 C [106] have described diverse changes in gene expression across a range of metabolic and signalling pathways upon reduction of the culture temperature. However, in the latter study substantial down-regulation of metabolic pathway gene expression was only observed at 22 C, in combination with decreased metabolic rates. In the study by Baik et al. [106] an associated proteomic analysis by 2D gel electrophoresis revealed relatively few changes in protein abundance (9 proteins), in accord with a previous analysis of the proteome of CHO cells at 30 C by the same technique [95] which showed that only 10 unidentified proteins had changed in abundance.
Several investigators have reported that increased medium osmolality increases cell-specific productivity. In these studies increased osmolality is often effected by the addition of sodium chloride [107] [108] [109] [110] or compatible solutes (osmoprotectants) such as glycine betaine that are less deleterious to cell viability [111] . Hyperosmolality typically induces cell cycle arrest in G 0/1 phase with an increase in cell volume and metabolic activity. For example, hyperosmotically stressed cells can exhibit increased amino acid uptake [112, 113] and glucose consumption rates [114] [115] [116] . With respect to recombinant protein production, increased cell-specific productivity does not always correlate with increased recombinant mRNA content. For example, no correlation between antibody secretion rate and mRNA content was observed during hyperosmotic culture of hybridoma cells [109] . In this study, it was shown that increased productivity arose from more rapid post-translational processing (folding and assembly) of the antibody. In contrast, other studies suggest that increased specific productivity of a recombinant MAb is correlated to increased recombinant mRNA level in osmotically-stressed CHO cells [108] or transfectomas [115] . This discrepancy between studies on hybridomas and engineered cells may be related to different cellular regulation of the transcription of 'homologous' Mab genes in hybridomas and recombinant Mab genes driven by heterologous viral promoters in engineered cells. For example, hyperosmotic stress does not substantially increase cellular Mab mRNA content in hybridoma cells [109] , but increased recombinant Mab transcription is observed in CHO and transfectoma cells in hyperosmotic medium [108, 115] . There is a limited understanding of the mechanisms of the osmotic stress response in mammalian cells. As in budding yeast, mammalian cell responses to osmostress are thought to be mediated by a variety of signalling cascades [117, 118] including those mediated by stress-activated protein kinases (SAPK's) such as c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases, which interact with a variety of transcription factors [119, 120] . Mammalian cells regularly exposed to osmotic stress typically respond to hyperosmolarity by cell cycle arrest in G 0/1 and G 2 /M, where p38 phosphorylates p53 in response to stress resulting in a p53-regulated inhibition of DNA replication [121] . Aside from signalling pathway induction both hyper-and hypoosmolarity have been shown to exert an effect on the constitutive secretory pathway; selectively blocking anterograde export from the ER and ER-to-Golgi intermediate compartment in a variety of mammalian cell types [122] .
Recent studies on the transcriptional response of hybridomas [123] and NS0 murine myeloma cells [116] to hyperosmotic shock have shed little light upon the concerted mechanisms of cell response to hyperosmolality. Both studies revealed that whilst relatively few genes (340 and 600, respectively) are differentially regulated (AE 2-fold change), diverse functional groups of genes are affected by medium hyperosmolality-both these reports exhibiting the complex nature of cellular response to hyperosmolality. However, whilst Shen and Sharfstein reported an equal mixture of up-and down-regulated genes across functional classes in hybridomas exposed to hyperosmolality (ca. 390 mOsm), Wu et al. [116] observed that $90% of differentially expressed genes in NS0 cells exposed to 450 mOsm were up-regulated. Considering both reports it is difficult to draw firm conclusions from the lists of differentially regulated genes, although in both cases genes associated with carbohydrate, amino acid and protein metabolism appear to be generally up-regulated in line with previous reports of increased metabolic flux in cells in hyperosmotic media. In comparison, two dimensional gel-based proteomic analysis of CHO cells in hyperosmotic media revealed very few significant changes in protein abundance [114] . Associated with the reduction in cell proliferation induced by hyperosmolality, the abundance of tubulins was reduced (some of which are presumably associated with the mitotic spindle), and the abundance of two glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase was increased.
In general, no coordinated pattern of hyperosmotic regulation emerges from these -omic studies. As for many functional properties of mammalian cell lines, this may be related to cell line specific variation in response to hyperosmotic environment [108] .
Generally, and in accord with the -omic data described earlier for changes in metabolic flux associated with mild-hypothermia (reduced metabolic flux) and hyperosmolality (increased metabolic flux), deliberate changes to the metabolic status of mammalian cells in culture have been reported to be associated with very limited, specific changes to the abundance of (primarily) metabolic genes and proteins. Following a previous proteomic investigation on the same experimental system [124] , Korke et al. [125] compared the transcriptome and proteome of hybridoma cells maintained in continuous culture at two different steady states. As per a previous report [126] , cells were maintained either at more efficient metabolic state obtained via a controlled, low glucose and glutamine feed/consumption rate with consequently low lactate production (low ÁL/ÁG ¼ 0.08) or, at a relatively inefficient ('overflow') metabolic state obtained at an uncontrolled glucose and glutamine feed rate (high ÁL/ÁG ¼ 1.4). Even at the substantially different metabolic flux states induced, observed changes in the transcriptome were small. Analysis by both cDNA microarray and Affymetrix GeneChip's revealed that only $1.2% of genes and/or EST's were differentially expressed, and similar numbers of genes were up-or down-regulated (e.g. with the cDNA microarray 19 genes were up-regulated at high ÁL/ÁG, whereas 24 genes were up-regulated at low ÁL/ÁG). The proteomic analysis by 2D gel electrophoresis revealed the 43 protein spots varied in abundance between high and low ÁL/ÁG states. Despite this moderate global effect of metabolic shift at the genome level, all three analyses yielded the same general conclusion, that glycolytic genes and proteins are differentially accumulated-an increased metabolic flux (high ÁL/ÁG, 3-5-fold increase in flux) is associated with an increased abundance of selected genes and proteins (1.4-3-fold). Whilst there was significant overlap between all analyses with respect to genes/proteins identified, only the glycolytic enzymes triosephosphate isomerase and enolase were identified by all methods as differentially expressed. These metabolic shift data correlate reasonably well with recent transcriptomic profiling of HEK293 cells producing a recombinant adenovirus during batch and fed-batch culture [127] . The latter culture system was maintained in a more efficient metabolic state by a controlled nutrient feeding strategy described by this group previously [128] , resulting in a 4-fold increase in viable cell concentration over batch culture. Decreased metabolic flux (glucose, lactate, ammonia and amino acids) during fed-batch culture was associated with a down-regulation of amino acid metabolism genes, tRNA synthetase genes, TCA cycle genes and some glycolytic genes, although genes coding for mitochondrial electron transport proteins were up-regulated. However, as for previous metabolic shift studies, the total number of differentially expressed genes was relatively small (1.1% of 18 656 microarray sequences exhibiting a >2-fold change) Data appertaining to cell cultures maintained in altered metabolic states also correlate with proteomic data from this laboratory which have shown that even though progressive changes in metabolic flux (glucose, glutamate and lactate uptake rates) occur during fed-batch culture of GS-NS0 cells producing a recombinant antibody, there are no correlating changes in the synthesis or abundance of 80 cellular proteins (including metabolic proteins) [30] . Similarly, a study by Pascoe et al. [129] on changes to the CHO cell proteome during fed-batch culture of two antibody-producing cell lines with different metabolic characteristics showed that, although a substantial proportion of proteins significantly changing in abundance were glycolytic enzymes, these did not alter in abundance in accordance with the observed changes in metabolite flux (glucose, lactate). For example, contrary to previous metabolic shift data, triosephosphate isomerase was significantly increased in abundance in both cell lines during a phase of culture where glucose uptake was declining.
Therefore, in general it would appear that large changes in metabolic flux can occur within the existing confines of the mammalian cell proteome (most metabolic enzymes operate well below their V max in mammalian cells), although, as per -omic reports, small changes in the abundance of specific regulatory enzymes, such as phosphofructokinase and pyruvate kinase may substantially affect flux. This concurs with genetic engineering studies which have shown that the generally sub-optimal efficiency of substrate utilization by mammalian cells in culture can be improved by very specific alterations to the abundance of single rate-limiting enzymes such as pyruvate carboxylase [130] . With respect to engineered mammalian cells in culture, metabolic efficiency does impact on volumetric titre of product, but primarily via the cells increased ability to accumulate new productive biomass rather than via a direct effect on specific productivity; Cruz et al. [131] demonstrated no effect of metabolic shift on qP in baby hamster kidney cells producing a recombinant fusion protein. Even though protein synthesis and secretion is a primary consumer of metabolic energy and precursors in mammalian cells [16] and sensitive to changes in energy supply [132] , recombinant protein synthesis may not account for a large proportion of total protein synthesis in engineered mammalian cells [51] .
GENETIC AND PHENOTYPIC STABILITY
Even though it is a regulatory requirement that production mammalian cell lines are clonally derived (from a single cell), mammalian cell populations are inherently genetically heterogeneous, and the associated functional heterogeneity underpins the ability of some cells in a population to survive in synthetic growth environments, achieve high rates of cell proliferation in culture [47] and efficiently manufacture recombinant proteins [50, 51] . Therefore, whilst exploitation of clonal genetic variation is necessary to generate productive cell lines capable of supporting biomanufacturing operations (e.g. 'adaptation' to proliferation in suspension culture), spontaneously arising genetic heterogeneity (genetic instability) also contributes some undesirable side effects. Clonally-derived cell lines can exhibit unpredictable and uncontrollable behaviour in vitro such as loss of productivity [46, 133] , variations in product modification reactions such as N-glycan processing and variation in growth rate [47] . With respect to the latter, even a minor advantage in growth rate will enable a clonally-derived population to overgrow a culture within a limited number of generations [134, 135] . Moreover, it is impossible to predict how a particular clone is 'programmed' to respond to changes in the culture environment relevant to upstream production (e.g. changes in pH, osmolality in the bioreactor) without actually evaluating its performance. Selection of functionally superior clones, and dealing with the consequences of clone-specific functional heterogeneity/instability and it's acquisition during sub-culture is timeconsuming and labour intensive [8] .
Very little is known about the origins of genetic instability in engineered mammalian cell lines. The most relevant and compelling evidence arises from a consideration of the genetic instability of cancer cells. Genetic instability is a defining feature of cancer [136] . Carcinogenesis proceeds via the acquisition of both chromosomal instability (aneuploidy) [137, 138] and clonal point mutations [139, 140] . In this context, the ability of cancer cells to become malignant (i.e. develop new functions such as tumour progression and metastasis) is thought to be associated with a 'mutator phenotype'-the acquisition of a higher rate of mutation or genetic instability in some cancer cells as a consequence of the loss of function of genes (point mutation, epigenetic events, chromosomal alterations) which confer genomic stability, such as those involved in DNA mismatch repair, excision repair, DNA polymerases, etc [141, 142] . Single mutations in 'mutator' genes can induce chromosomal instability and/or increase genomic mutation rate [143, 144] .
Epigenetic changes may also be relevant and are implicated in the development of some cancers. The best studied of these processes is heritable transcriptional repression of genes caused by aberrant DNA hypermethylation of their promoters and histone deacetylation. DNA methylation and histone acetylation are known to be intimately linked, so that global hypomethylation might be expected to lead to global alterations in the level of histone acetylation and vice versa [145] . It is apparent that epigenetic changes can, just as for gene mutations, perturb multiple key pathways in ways that promote cancer cell evolution [146] . For example, methylation of the DNA repair genes can lead to an increased frequency of mutations [147] and hypermethylation of the promoter of the mitotic checkpoint protein BubR1 can promote chromosomal instability [148] .
Highly relevant to the maintenance of transformed mammalian host cells in culture, such as CHO cells, it is likely that the genetic instability of cancer cells is substantially promoted by the hypoxic microenvironment of tumours by a variety of mechanisms [149] . For example, it has been demonstrated that cycles of hypoxia-reoxygenation result in DNA replication in CHO cells, with an amplification in dihydroxyfolate gene expression and consequent resistance to methotrexate [150] . CHO cell lines expressing a reporter GFP gene have recently been shown to exhibit instability in recombinant gene expression [46] , although this was not apparently correlated with either the significant chromosomal instability observed or the number of recombinant gene copies. The latter is significant because it may be argued that maintenance of a low plasmid copy number avoids effects such as repeatinduced gene silencing [151] which may be expected as recombinant genes tend to integrate at a single site [46, 152] . These data do not support the hypothesis that loss of cell-specific production rate is a consequence of chromosomal instability per se.
Considering the above, a population dynamic model in which mammalian host cell populations employ randomly arising genetic heterogeneity to acquire new and useful functions in a selective environment (e.g. ability to grow autonomously in a synthetic environment, cope/avoid the stress of recombinant protein production) is entirely consistent with models of cancer cell progression deriving from genetic instability [153] . However, it is also consistent with the notion that increased genetic instability/evolution will provide a mechanism to enrich cell populations with cells that can avoid the burden of recombinant protein production. For example, in a cell line development context, the ability of a transfectant to mutate more frequently may confer an advantage with respect to ease of 'adaptation' to a bioreactor environment (i.e. selection of a genetically variant cell with a growth advantage in the synthetic environment). In this way, increased genetic instability may be a trait 'built-in' to clonally derived populations and thus directly linked to genetic instability in product formation. We anticipate that genome-level analysis of mammalian cell production vehicles would substantially enrich our understanding of the causes of genetic instability.
CONTROL OF PRODUCT MOLECULAR HETEROGENEITY
Recombinant proteins produced by mammalian expression systems can be subject to numerous post-translational modifications, which can result in a structurally heterogeneous product. Glycosylation is the most extensive of all post-translational modifications and for proteins destined for therapeutic use this source of molecular diversity is of particular significance to industry and regulatory agencies [154] . Distinct protein glycoforms may possess different properties such as biological activity, receptor binding, stability, immunogenicity and clearance rate in vivo. In the case of recombinant MAb's, the presence of N-glycans at Asn 297 of the heavy chain Fc region is frequently essential for therapeutic efficacy as this post-translational modification has been shown to be necessary for biological activities that harness immune system effector functions; both antibody dependent cell cytotoxicity (ADCC) and complement mediated lysis (CML). Variation in oligosaccharide structures can play a significant role in modulating ADCC and CML activities [155] . Therefore, strategies to modulate the N-glycosylation of recombinant proteins are generically relevant to the use of these molecules in the clinic. However, N-glycosylation is a complex multigenic process, ultimately involving hundreds of degradative and synthetic reactions as well as precursor transport processes between different cellular compartments. Accordingly there are numerous documented examples of cell type and even cell line-specific glycan processing, where genetic heterogeneity in glycan processing events in the cell can lead to altered molecular heterogeneity of the secreted glycoprotein product. For example, NS0 cells differ from CHO cells in that they are able to perform specific N-glycan processing reactions such as the addition of a-linked galactose residues [156] . In addition, CHO cells are also known to lack N-acetylglucosaminyltransferase III (GNTIII) activity; this confers a bisecting GlcNAc to N-glycans, which has been shown to increase the in vitro ADCC activity of MAb's [157, 158] . In this regard, cell engineering strategies to eliminate or add specific glycan processing reactions have met with some success (e.g. increased sialic acid [159] ; reduced core fucose [160] ). However, numerous cell culture variables have been shown to affect product glycosylation (culture time, dissolved oxygen, culture medium, catabolite accumulation, precursor availability, etc); and it is still not understood how to control this complex, dynamic cellular system in the bioreactor in order to achieve a recombinant glycoprotein product with a consistent or desirable glycosylation profile.
Mathematical models of N-glycosylation have been published which effectively treat N-glycan processing in the Golgi compartments as a series of continuous well-mixed reactors or plug-flow reactors [161] [162] [163] . These models are designed to predict the consequences (for N-glycan processing) of variation in a variety of parameters such as glycan processing enzyme level, nucleotide sugar precursor availability or substrate residence time in the context of a compartmentalized system. However, the effect of key process development variables such as cellspecific productivity remain difficult to predict as the means by which cells attain high specific productivity are not understood themselves, and may involve changes to intracellular processing machinery [51] . It seems more likely that the interactive cellular mechanisms behind both N-glycosylation and specific productivity, and their dynamic variation during culture and in response to culture variables, will be cell-line specific-another example of idiosyncratic genetic heterogeneity. Harcum and colleagues have shown that the expression of key glycosylation pathway (or related) genes in CHO cells vary in their sensitivity to cell carbon source [164] , or increased concentrations of toxic by-products such as ammonium, which is known to affect N-glycan processing [165, 166] . Lastly, whilst the modelling studies predict how to re-align N-glycan processing towards, for example, a homogeneous glycoprotein product with uniform N-glycans, the cell engineering necessary would involve far more than one enzyme as no single enzyme can effectively channel flux to a desirable glycoform [163] .
CONCLUSION
Arguably most -omic studies on mammalian cell factories published to date are effectively sampling the consequential effects of complex regulatory or signalling events only at a single layer of cell organization. These approaches have a limited ability to aid our mechanistic understanding of cell function in vitro or our ability to control it. Clearly, to realize the potential of systems biotechnology or even to effectively implement inverse engineering as a tool for cell engineering [9] , more exhaustive analysis and dynamic integration of -omic datasets is necessary [11] , broadly implemented across the multiple layers of cell organization.
Key Points
The increasing demand for recombinant therapeutic proteins in the clinic demands that the biopharmaceutical industry continues to develop high-yielding mammalian cell-based production systems. The functional characteristics of mammalian cells engineered to produce recombinant proteins are not well understood at a systems level. Systems biology has created a new set of tools that will direct future engineering strategies to develop high-yielding mammalian cell factories.
